$6M boost to drive industrial-scale Proteomics facility in WA
The company will partner with The University of Western Australia (UWA), the Western Australian Government and life science research collaborator BioPlatforms Australia to develop its world-class Perth facility. The partners want to target a growing market for high-throughput precision diagnostics across medicine and agriculture.
Proteomics and UWA will each kick $1 million into the kitty for the three-year project to develop an accredited protein biomarker analysis platform capable of helping push advances in the two critical sectors.
The Proteomics and UWA laboratories collaborate to bring together scientific and technological know-how to tease out the answers to everyday problems in health, agriculture and environmental sciences respectively, focusing on the emerging proteomics field.
Proteomics researchers work on identifying and measuring the changes in proteins within cells. Unlike DNA, proteins can change - studying them allows scientists to develop diagnostic tests that can detect diseases earlier and allow doctors to tailor treatments to their patients.
'This facility can become a national hub for precision diagnostic testing across clinical and agricultural proteomics.'
Proteomics International managing director Dr Richard Lipscombe
In agriculture, it could be used to guide grain selection or sowing decisions to improve yield and sustainability, for example. This may become particularly significant given the world's growing population and drying climate, which means farmers must increasingly work to maximise yields while they safeguard crops against drought, salinity, weeds and pests.
Proteomics International managing director Dr Richard Lipscombe said: 'This facility can become a national hub for precision diagnostic testing across clinical and agricultural proteomics. Extending our recent successful capital raise with state-of-the-art infrastructure to analyse thousands of samples at industrial scale, we can turn biological insight into real-world solutions - whether that's improving outcomes for patients with chronic diseases or selecting better crop varieties to address food security.'
Proteomics says achieving a new nationally accredited technology platform would significantly boost the facility's capacity for fast and accurate screening, help roll out diagnostic tests for clinical use and enable it to test large sets of agricultural and environmental samples.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Age
21 hours ago
- The Age
$6M boost to drive industrial-scale Proteomics facility in WA
Proteomics International will expand its Perth facility into a national diagnostics hub using a $6 million funding boost to develop a new protein biomarker analysis platform for industrial-scale precision medical and agricultural screening. The company will partner with The University of Western Australia (UWA), the Western Australian Government and life science research collaborator BioPlatforms Australia to develop its world-class Perth facility. The partners want to target a growing market for high-throughput precision diagnostics across medicine and agriculture. Proteomics and UWA will each kick $1 million into the kitty for the three-year project to develop an accredited protein biomarker analysis platform capable of helping push advances in the two critical sectors. The Proteomics and UWA laboratories collaborate to bring together scientific and technological know-how to tease out the answers to everyday problems in health, agriculture and environmental sciences respectively, focusing on the emerging proteomics field. Proteomics researchers work on identifying and measuring the changes in proteins within cells. Unlike DNA, proteins can change - studying them allows scientists to develop diagnostic tests that can detect diseases earlier and allow doctors to tailor treatments to their patients. 'This facility can become a national hub for precision diagnostic testing across clinical and agricultural proteomics.' Proteomics International managing director Dr Richard Lipscombe In agriculture, it could be used to guide grain selection or sowing decisions to improve yield and sustainability, for example. This may become particularly significant given the world's growing population and drying climate, which means farmers must increasingly work to maximise yields while they safeguard crops against drought, salinity, weeds and pests. Proteomics International managing director Dr Richard Lipscombe said: 'This facility can become a national hub for precision diagnostic testing across clinical and agricultural proteomics. Extending our recent successful capital raise with state-of-the-art infrastructure to analyse thousands of samples at industrial scale, we can turn biological insight into real-world solutions - whether that's improving outcomes for patients with chronic diseases or selecting better crop varieties to address food security.' Proteomics says achieving a new nationally accredited technology platform would significantly boost the facility's capacity for fast and accurate screening, help roll out diagnostic tests for clinical use and enable it to test large sets of agricultural and environmental samples.
Sydney Morning Herald
21 hours ago
- Sydney Morning Herald
$6M boost to drive industrial-scale Proteomics facility in WA
Proteomics International will expand its Perth facility into a national diagnostics hub using a $6 million funding boost to develop a new protein biomarker analysis platform for industrial-scale precision medical and agricultural screening. The company will partner with The University of Western Australia (UWA), the Western Australian Government and life science research collaborator BioPlatforms Australia to develop its world-class Perth facility. The partners want to target a growing market for high-throughput precision diagnostics across medicine and agriculture. Proteomics and UWA will each kick $1 million into the kitty for the three-year project to develop an accredited protein biomarker analysis platform capable of helping push advances in the two critical sectors. The Proteomics and UWA laboratories collaborate to bring together scientific and technological know-how to tease out the answers to everyday problems in health, agriculture and environmental sciences respectively, focusing on the emerging proteomics field. Proteomics researchers work on identifying and measuring the changes in proteins within cells. Unlike DNA, proteins can change - studying them allows scientists to develop diagnostic tests that can detect diseases earlier and allow doctors to tailor treatments to their patients. 'This facility can become a national hub for precision diagnostic testing across clinical and agricultural proteomics.' Proteomics International managing director Dr Richard Lipscombe In agriculture, it could be used to guide grain selection or sowing decisions to improve yield and sustainability, for example. This may become particularly significant given the world's growing population and drying climate, which means farmers must increasingly work to maximise yields while they safeguard crops against drought, salinity, weeds and pests. Proteomics International managing director Dr Richard Lipscombe said: 'This facility can become a national hub for precision diagnostic testing across clinical and agricultural proteomics. Extending our recent successful capital raise with state-of-the-art infrastructure to analyse thousands of samples at industrial scale, we can turn biological insight into real-world solutions - whether that's improving outcomes for patients with chronic diseases or selecting better crop varieties to address food security.' Proteomics says achieving a new nationally accredited technology platform would significantly boost the facility's capacity for fast and accurate screening, help roll out diagnostic tests for clinical use and enable it to test large sets of agricultural and environmental samples.
The Age
2 days ago
- The Age
Milestone first patent for Proteomics simple endometriosis test
In a milestone moment, ASX-listed diagnostics innovator Proteomics International Laboratories has achieved its first patent globally in Japan for its simple 'traffic light' diagnostic blood test for endometriosis. The decision will protect the company's intellectual property rights for its PromarkerEndo technology in the world's fourth-largest healthcare market until March 16, 2041. Proteomics says Japan's healthcare sector already widely uses in vitro diagnostics and precision medicine technologies to customise treatments for patients and help deliver better patient outcomes. The company is planning to start an international commercial roll-out of the device within months using its existing direct-to-consumer channels, while also tapping into general practitioners and women's health specialists. 'This is a significant achievement because it validates the novelty of PromarkerEndo, our world-first blood test for endometriosis.' Proteomics International managing director Dr Richard Lipscombe Proteomics International managing director Dr Richard Lipscombe said: 'Securing patent protection for our diagnostic technology in this region is a key step in our global commercialisation pathway and provides a strong foundation for potential partnerships, licensing, and regulatory advancement.' PromarkerEndo promises to revolutionise women's reproductive healthcare by delivering the first clinically viable, real-world, non-invasive diagnostic test for a disease affecting one in nine women and girls. Estimates suggest endometriosis costs the Australian economy nearly $10 billion annually. Its symptoms can be devastating for women, but it has historically been difficult to diagnose. It can take up to seven years on average for women to be diagnosed with endometriosis, using painful and invasive laparoscopy and tissue biopsies, performed under anaesthetics. For the first time, doctors may instead be able to turn to PromarkerEndo as a frontline tool in detecting endometriosis in symptomatic patients. The device uses a universal 'traffic light' risk score - low, moderate or high - to indicate a patient's likelihood of having the disease.
